Andrew Cridland

Andrew Cridland currently serves as Associate Director at RXCELERATE LIMITED since June 2024. Previously, Andrew held the position of Principal Scientist at WaveBreak from December 2019 to May 2024, leading the alpha-synuclein aggregation inhibition project which resulted in the drug candidate WTX-607 for Parkinson’s disease. Prior to that, Andrew worked at Charles River Laboratories from August 2011 to November 2019 as Team Leader, managing cross-departmental projects and a team of chemists, and as Senior Scientist, where significant contributions included delivering clinical candidates and conducting internal training. Andrew's earlier experience includes senior scientist roles at Eisai US and GSK, and a scientist position at AstraZeneca. Andrew earned a PhD in Organic Chemistry from the University of Nottingham between 2003 and 2006.